Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFCT-1701 DICIPLE
2024-514586-20-01Phase 3Completed
- Sponsor
- IFCT
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in non-small cell lung cancer (NSCLC) comparing Continuation nivolumab + ipilimumab with Observation only after induction (2 arms). Primary endpoint: Progression Free Survival (PFS1). Started May 2018; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-514586-20-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514586-20-01.